NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (Aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure That Were Also Treated with Remdesivir and Continued to Progress

NRx Pharmaceuticals, Inc. announced that it has filed a new breakthrough therapy designation request with the US FDA focused on a subgroup of patients with Critical COVID-19 that in addition to aviptadil or placebo were also treated with remdesivir.